A randomized, double-blind, parallel-group, phase III study of shortening the dosing interval of subcutaneous tocilizumab monotherapy in patients with rheumatoid arthritis and an inadequate response to subcutaneous tocilizumab every other week: Results of the 12-week double-blind period

著录项

• 来源
  《Modern rheumatology》 |2018年第1期|共9页
• 作者

  Ogata Atsushi; Tanaka Yoshiya; Ishii Tomonori; Kaneko Motohide; Miwa Hiroko; Ohsawa Shino;

  展开▼
• 作者单位

  Osaka Univ Grad Sch Med Dept Resp Med Allergy &

  Rheumat Dis Osaka Japan;

  Univ Occupat &

  Environm Hlth Sch Med Dept Internal Med 1 Kitakyushu Fukuoka Japan;

  Tohoku Univ Grad Sch Med Dept Hematol &

  Rheumatol Sendai Miyagi Japan;

  Kaneko Internal Med Rheumatol Clin Kawaguchi Saitama Japan;

  Chugai Pharmaceut Co Ltd Tokyo Japan;

  Chugai Pharmaceut Co Ltd Tokyo Japan;

  展开▼
• 收录信息
• 原文格式 PDF
• 正文语种 eng
• 中图分类 免疫性疾病;
• 关键词

  Dose interval; rheumatoid arthritis; subcutaneous; tocilizumab;

  机译：剂量间隔;类风湿性关节炎;皮下;拍摄;